Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids.
With a new method we measured the saturated very long chain fatty acids in the plasma of adrenoleukodystrophy (ALD) hemizygotes, ALD heterozygotes, and controls. ALD hemizygotes showed increased levels of hexacosanoate (C26 fatty acid) which represented 0.081 +/- 0.0066% (SEM) of total fatty acids, compared to 0.015 +/- 0.0032% in the controls. C25, C24, and C23 fatty acids were also increased, but the C22 and C20 fatty acids were normal. C26 levels were also increased in most ALD heterozygotes, with a mean level 0.057 +/- 0.0063% of total fatty acids. The technique can be used for diagnosis and carrier identification, and in the evaluation of therapy.
D000293:Adolescent; D000309:Adrenal Insufficiency / Q000097:blood* / Q000235:genetics; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D002784:Cholesterol / Q000378:metabolism; D002549:Diffuse Cerebral Sclerosis of Schilder / Q000097:blood* / Q000175:diagnosis / Q000235:genetics; D005227:Fatty Acids / Q000097:blood* / Q000235:genetics; D005260:Female; D005347:Fibroblasts / Q000032:analysis; D006579:Heterozygote; D006801:Humans; D007223:Infant; D008297:Male; D008661:Metabolism, Inborn Errors / Q000378:metabolism; D008875:Middle Aged; D012867:Skin / Q000032:analysis
D005227:Fatty Acids; D002784:Cholesterol